+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Myasthenia Gravis Treatment Market Size, Share & Industry Trends Analysis Report By End-use (Hospitals, Clinics and Others), By Type, By Regional Outlook and Forecast, 2023 - 2030

  • PDF Icon

    Report

  • 216 Pages
  • November 2023
  • Region: Global
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5916877
Description Jump to:
The Global Myasthenia Gravis Treatment Market size is expected to reach $3.8 billion by 2030, rising at a market growth of 9.2% CAGR during the forecast period.

Better awareness and improved diagnostic techniques led to more cases being identified, increasing the demand for myasthenia gravis treatments, including chronic immunomodulators. Therefore, chronic immunomodulators segment captured $127.2 million revenue in the market in 2022. Research into autoimmune diseases, including myasthenia gravis, has spurred the development of newer and more effective chronic immunomodulators. Companies invest in developing improved formulations or alternative medications with better efficacy and fewer side effects. Thus, due to these factors, the segment will witness increased demand in the coming years. Some of the factors impacting the market are increased awareness and diagnosis of myasthenia gravis, growing usage and development of biological drugs and targeted therapies, and lack of treatment options for myasthenia gravis.

Early diagnosis means more identified cases of myasthenia gravis. This expands the patient pool seeking treatment. As more patients are diagnosed early, there's a higher demand for treatments, medications, and therapies, potentially creating a larger opportunity for pharmaceutical companies and healthcare providers. Early intervention often means a more manageable disease course. Moreover, as more attention is drawn to the disease, regulatory bodies and funding agencies might show increased interest. This can result in expedited review processes, regulatory support, and potentially increased funding for research and development in the myasthenia gravis treatment space. Additionally, unlike more generalized immunosuppressive treatments, biologics and targeted therapies focus on specific components of the immune system responsible for the autoimmune response in myasthenia gravis. For instance, some drugs may target B cells, producing autoantibodies that attack the neuromuscular junction. Moreover, introducing biological drugs has spurred increased research and clinical trials focusing on these targeted therapies. This ongoing research contributes to an expanding knowledge base and potential for further advancements in treatment options for myasthenia gravis. These aspects will drive the expansion of the market.

However, myasthenia gravis is known for its heterogeneity, meaning the symptoms, severity, and treatment response can differ significantly among individuals. What works well for one patient might not be as effective for another. This makes it challenging to find a universally effective treatment. Many medications commonly used to manage myasthenia gravis symptoms can lead to various side effects. These factors are expected to hamper the growth of the market.

Additionally, many individuals with chronic conditions like MG faced disruptions in their routine healthcare services due to overwhelmed healthcare systems, reallocation of resources, and restrictions on non-essential services during the pandemic's peak. Restrictions on in-person consultations limited access to specialized care from neurologists and other MG specialists, impacting disease management and individualized treatment plans. The unavailability or delay in receiving prescribed medications led to interruptions in the treatment, potentially impacting the control of MG symptoms. Inadequate access to essential medications resulted in disease exacerbations or flares, leading to increased weakness, fatigue, and other symptoms associated with MG. Therefore, the COVID-19 pandemic had a negative impact on the myasthenia gravis treatment market.

Type Outlook

On the basis of type, the market is segmented into cholinesterase inhibitors, chronic immunomodulators, monoclonal antibodies, rapid immunotherapies, thymectomy, and others. The monoclonal antibodies segment recorded the maximum revenue share in the market in 2022. Monoclonal antibodies are a type of biological therapy that targets certain immune system components suspected to be involved in the etiology of myasthenia gravis.

End-Use Outlook

Based on end-use, the market is divided into hospitals, clinics, and others. In 2022, the clinics segment witnessed a substantial revenue share in the market. Clinics specifically dedicated to neuromuscular disorders, including myasthenia gravis, provide comprehensive care with neurologists, immunologists, and other specialists experienced in managing this condition. The demand for specialized care could fuel the growth of such clinics.

Regional Outlook

By region, the market is segmented into North America, Europe, Asia Pacific, and LAMEA. The North America segment procured the highest revenue share in the market in 2022. North America has seen a considerable prevalence of myasthenia gravis. Better diagnostic capabilities and increased awareness among healthcare professionals have led to more accurate and timely diagnoses of the condition, driving the demand for treatments.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca PLC (Alexion Pharmaceuticals, Inc.), Octapharma AG, Novartis AG, Pfizer, Inc., Allergan PLC (AbbVie, Inc.), F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC (GSK), Bausch Health Companies Inc., Kedrion S.p.A, and Zydus Lifesciences Ltd.

Scope of the Study

Market Segments Covered in the Report:

By End-use
  • Hospitals
  • Clinics
  • Others
By Type
  • Monoclonal Antibodies
  • Thymectomy
  • Cholinesterase Inhibitors
  • Chronic Immunomodulators
  • Rapid Immunotherapies
  • Others
By Geography
  • North America
  • US
  • Canada
  • Mexico
  • Rest of North America
  • Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
  • LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Key Market Players

List of Companies Profiled in the Report:

  • AstraZeneca PLC (Alexion Pharmaceuticals, Inc.)
  • Octapharma AG
  • Novartis AG
  • Pfizer, Inc.
  • Allergan PLC (AbbVie, Inc.)
  • F.Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC (GSK)
  • Bausch Health Companies Inc.
  • Kedrion S.p.A
  • Zydus Lifesciences Ltd.

Unique Offerings

  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Myasthenia Gravis Treatment Market, by End-use
1.4.2 Global Myasthenia Gravis Treatment Market, by Type
1.4.3 Global Myasthenia Gravis Treatment Market, by Geography
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.3 Porter Five Forces Analysis
Chapter 4. Global Myasthenia Gravis Treatment Market by End-use
4.1 Global Hospitals Market by Region
4.2 Global Clinics Market by Region
4.3 Global Others Market by Region
Chapter 5. Global Myasthenia Gravis Treatment Market by Type
5.1 Global Monoclonal Antibodies Market by Region
5.2 Global Thymectomy Market by Region
5.3 Global Cholinesterase Inhibitors Market by Region
5.4 Global Chronic Immunomodulators Market by Region
5.5 Global Rapid Immunotherapies Market by Region
5.6 Global Others Market by Region
Chapter 6. Global Myasthenia Gravis Treatment Market by Region
6.1 North America Myasthenia Gravis Treatment Market
6.1.1 North America Myasthenia Gravis Treatment Market by End-use
6.1.1.1 North America Hospitals Market by Country
6.1.1.2 North America Clinics Market by Country
6.1.1.3 North America Others Market by Country
6.1.2 North America Myasthenia Gravis Treatment Market by Type
6.1.2.1 North America Monoclonal Antibodies Market by Country
6.1.2.2 North America Thymectomy Market by Country
6.1.2.3 North America Cholinesterase Inhibitors Market by Country
6.1.2.4 North America Chronic Immunomodulators Market by Country
6.1.2.5 North America Rapid Immunotherapies Market by Country
6.1.2.6 North America Others Market by Country
6.1.3 North America Myasthenia Gravis Treatment Market by Country
6.1.3.1 US Myasthenia Gravis Treatment Market
6.1.3.1.1 US Myasthenia Gravis Treatment Market by End-use
6.1.3.1.2 US Myasthenia Gravis Treatment Market by Type
6.1.3.2 Canada Myasthenia Gravis Treatment Market
6.1.3.2.1 Canada Myasthenia Gravis Treatment Market by End-use
6.1.3.2.2 Canada Myasthenia Gravis Treatment Market by Type
6.1.3.3 Mexico Myasthenia Gravis Treatment Market
6.1.3.3.1 Mexico Myasthenia Gravis Treatment Market by End-use
6.1.3.3.2 Mexico Myasthenia Gravis Treatment Market by Type
6.1.3.4 Rest of North America Myasthenia Gravis Treatment Market
6.1.3.4.1 Rest of North America Myasthenia Gravis Treatment Market by End-use
6.1.3.4.2 Rest of North America Myasthenia Gravis Treatment Market by Type
6.2 Europe Myasthenia Gravis Treatment Market
6.2.1 Europe Myasthenia Gravis Treatment Market by End-use
6.2.1.1 Europe Hospitals Market by Country
6.2.1.2 Europe Clinics Market by Country
6.2.1.3 Europe Others Market by Country
6.2.2 Europe Myasthenia Gravis Treatment Market by Type
6.2.2.1 Europe Monoclonal Antibodies Market by Country
6.2.2.2 Europe Thymectomy Market by Country
6.2.2.3 Europe Cholinesterase Inhibitors Market by Country
6.2.2.4 Europe Chronic Immunomodulators Market by Country
6.2.2.5 Europe Rapid Immunotherapies Market by Country
6.2.2.6 Europe Others Market by Country
6.2.3 Europe Myasthenia Gravis Treatment Market by Country
6.2.3.1 Germany Myasthenia Gravis Treatment Market
6.2.3.1.1 Germany Myasthenia Gravis Treatment Market by End-use
6.2.3.1.2 Germany Myasthenia Gravis Treatment Market by Type
6.2.3.2 UK Myasthenia Gravis Treatment Market
6.2.3.2.1 UK Myasthenia Gravis Treatment Market by End-use
6.2.3.2.2 UK Myasthenia Gravis Treatment Market by Type
6.2.3.3 France Myasthenia Gravis Treatment Market
6.2.3.3.1 France Myasthenia Gravis Treatment Market by End-use
6.2.3.3.2 France Myasthenia Gravis Treatment Market by Type
6.2.3.4 Russia Myasthenia Gravis Treatment Market
6.2.3.4.1 Russia Myasthenia Gravis Treatment Market by End-use
6.2.3.4.2 Russia Myasthenia Gravis Treatment Market by Type
6.2.3.5 Spain Myasthenia Gravis Treatment Market
6.2.3.5.1 Spain Myasthenia Gravis Treatment Market by End-use
6.2.3.5.2 Spain Myasthenia Gravis Treatment Market by Type
6.2.3.6 Italy Myasthenia Gravis Treatment Market
6.2.3.6.1 Italy Myasthenia Gravis Treatment Market by End-use
6.2.3.6.2 Italy Myasthenia Gravis Treatment Market by Type
6.2.3.7 Rest of Europe Myasthenia Gravis Treatment Market
6.2.3.7.1 Rest of Europe Myasthenia Gravis Treatment Market by End-use
6.2.3.7.2 Rest of Europe Myasthenia Gravis Treatment Market by Type
6.3 Asia Pacific Myasthenia Gravis Treatment Market
6.3.1 Asia Pacific Myasthenia Gravis Treatment Market by End-use
6.3.1.1 Asia Pacific Hospitals Market by Country
6.3.1.2 Asia Pacific Clinics Market by Country
6.3.1.3 Asia Pacific Others Market by Country
6.3.2 Asia Pacific Myasthenia Gravis Treatment Market by Type
6.3.2.1 Asia Pacific Monoclonal Antibodies Market by Country
6.3.2.2 Asia Pacific Thymectomy Market by Country
6.3.2.3 Asia Pacific Cholinesterase Inhibitors Market by Country
6.3.2.4 Asia Pacific Chronic Immunomodulators Market by Country
6.3.2.5 Asia Pacific Rapid Immunotherapies Market by Country
6.3.2.6 Asia Pacific Others Market by Country
6.3.3 Asia Pacific Myasthenia Gravis Treatment Market by Country
6.3.3.1 China Myasthenia Gravis Treatment Market
6.3.3.1.1 China Myasthenia Gravis Treatment Market by End-use
6.3.3.1.2 China Myasthenia Gravis Treatment Market by Type
6.3.3.2 Japan Myasthenia Gravis Treatment Market
6.3.3.2.1 Japan Myasthenia Gravis Treatment Market by End-use
6.3.3.2.2 Japan Myasthenia Gravis Treatment Market by Type
6.3.3.3 India Myasthenia Gravis Treatment Market
6.3.3.3.1 India Myasthenia Gravis Treatment Market by End-use
6.3.3.3.2 India Myasthenia Gravis Treatment Market by Type
6.3.3.4 South Korea Myasthenia Gravis Treatment Market
6.3.3.4.1 South Korea Myasthenia Gravis Treatment Market by End-use
6.3.3.4.2 South Korea Myasthenia Gravis Treatment Market by Type
6.3.3.5 Singapore Myasthenia Gravis Treatment Market
6.3.3.5.1 Singapore Myasthenia Gravis Treatment Market by End-use
6.3.3.5.2 Singapore Myasthenia Gravis Treatment Market by Type
6.3.3.6 Malaysia Myasthenia Gravis Treatment Market
6.3.3.6.1 Malaysia Myasthenia Gravis Treatment Market by End-use
6.3.3.6.2 Malaysia Myasthenia Gravis Treatment Market by Type
6.3.3.7 Rest of Asia Pacific Myasthenia Gravis Treatment Market
6.3.3.7.1 Rest of Asia Pacific Myasthenia Gravis Treatment Market by End-use
6.3.3.7.2 Rest of Asia Pacific Myasthenia Gravis Treatment Market by Type
6.4 LAMEA Myasthenia Gravis Treatment Market
6.4.1 LAMEA Myasthenia Gravis Treatment Market by End-use
6.4.1.1 LAMEA Hospitals Market by Country
6.4.1.2 LAMEA Clinics Market by Country
6.4.1.3 LAMEA Others Market by Country
6.4.2 LAMEA Myasthenia Gravis Treatment Market by Type
6.4.2.1 LAMEA Monoclonal Antibodies Market by Country
6.4.2.2 LAMEA Thymectomy Market by Country
6.4.2.3 LAMEA Cholinesterase Inhibitors Market by Country
6.4.2.4 LAMEA Chronic Immunomodulators Market by Country
6.4.2.5 LAMEA Rapid Immunotherapies Market by Country
6.4.2.6 LAMEA Others Market by Country
6.4.3 LAMEA Myasthenia Gravis Treatment Market by Country
6.4.3.1 Brazil Myasthenia Gravis Treatment Market
6.4.3.1.1 Brazil Myasthenia Gravis Treatment Market by End-use
6.4.3.1.2 Brazil Myasthenia Gravis Treatment Market by Type
6.4.3.2 Argentina Myasthenia Gravis Treatment Market
6.4.3.2.1 Argentina Myasthenia Gravis Treatment Market by End-use
6.4.3.2.2 Argentina Myasthenia Gravis Treatment Market by Type
6.4.3.3 UAE Myasthenia Gravis Treatment Market
6.4.3.3.1 UAE Myasthenia Gravis Treatment Market by End-use
6.4.3.3.2 UAE Myasthenia Gravis Treatment Market by Type
6.4.3.4 Saudi Arabia Myasthenia Gravis Treatment Market
6.4.3.4.1 Saudi Arabia Myasthenia Gravis Treatment Market by End-use
6.4.3.4.2 Saudi Arabia Myasthenia Gravis Treatment Market by Type
6.4.3.5 South Africa Myasthenia Gravis Treatment Market
6.4.3.5.1 South Africa Myasthenia Gravis Treatment Market by End-use
6.4.3.5.2 South Africa Myasthenia Gravis Treatment Market by Type
6.4.3.6 Nigeria Myasthenia Gravis Treatment Market
6.4.3.6.1 Nigeria Myasthenia Gravis Treatment Market by End-use
6.4.3.6.2 Nigeria Myasthenia Gravis Treatment Market by Type
6.4.3.7 Rest of LAMEA Myasthenia Gravis Treatment Market
6.4.3.7.1 Rest of LAMEA Myasthenia Gravis Treatment Market by End-use
6.4.3.7.2 Rest of LAMEA Myasthenia Gravis Treatment Market by Type
Chapter 7. Company Profiles
7.1 AstraZeneca PLC (Alexion Pharmaceuticals, Inc.)
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Regional Analysis
7.1.4 Research & Development Expenses
7.1.5 Recent strategies and developments:
7.1.5.1 Approval and Trails:
7.1.6 SWOT Analysis
7.2 Octapharma AG
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Research & Development Expenses
7.3 Novartis AG
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expense
7.3.5 SWOT Analysis
7.4 Pfizer, Inc.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional & Segmental Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
7.4.5.1 Approval and Trails:
7.4.6 SWOT Analysis
7.5 Allergan PLC (AbbVie, Inc.)
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional Analysis
7.5.1 Research & Development Expense
7.5.2 SWOT Analysis
7.6 F. Hoffmann-La Roche Ltd.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expense
7.6.5 SWOT Analysis
7.7 GlaxoSmithKline PLC (GSK)
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional Analysis
7.7.4 Research & Development Expense
7.7.5 SWOT Analysis
7.8 Bausch Health Companies Inc
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expenses
7.8.5 SWOT Analysis
7.9 Kedrion S.p.A
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Research & Development Expenses
7.9.4 SWOT Analysis
7.10. Zydus Lifesciences Ltd.
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Segmental and Regional Analysis
7.10.4 Research & Development Expense
7.10.5 SWOT Analysis
Chapter 8. Winning imperatives of Myasthenia Gravis Treatment Market

Companies Mentioned

  • AstraZeneca PLC (Alexion Pharmaceuticals, Inc.)
  • Octapharma AG
  • Novartis AG
  • Pfizer, Inc.
  • Allergan PLC (AbbVie, Inc.)
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC (GSK)
  • Bausch Health Companies Inc.
  • Kedrion S.p.A
  • Zydus Lifesciences Ltd.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Myasthenia Gravis Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030 - Product Image

Myasthenia Gravis Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030

  • Report
  • 150 Pages
  • Global
From
Myasthenia Gravis Treatment Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2019-2029F - Product Image

Myasthenia Gravis Treatment Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2019-2029F

  • Report
  • 185 Pages
  • Global
From
Myasthenia Gravis Treatment Global Market Report 2024 - Product Image

Myasthenia Gravis Treatment Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Myasthenia Gravis Treatment Market: Forecast and Trends - Product Image

Myasthenia Gravis Treatment Market: Forecast and Trends

  • Report
  • 120 Pages
  • Global
From
Myasthenia Gravis Treatment - Global Strategic Business Report - Product Image

Myasthenia Gravis Treatment - Global Strategic Business Report

  • Report
  • 89 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.